Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma

Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma

Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has been approved for the treatment...

Full description

Bibliographic Details
Main Authors: Fonseca, Paula J., Uriol, Esther, Galván, José A., Álvarez, Carlos, Pérez, Quionia, Villanueva, Noemi, Berros, José P., Izquierdo, Marta, Viéitez, José M.
Format: Online
Language:English
Published: S. Karger AG 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764965/

Similar Items

Similar Items